• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Study: Hill-Rom’s Metaneb System lowers risk of post-operative pulmonary complications

February 28, 2018 By Sarah Faulkner

Researchers at the 47th Society of Critical Care Medicine reported this week that Hill-Rom‘s (NYSE:HRC) Metaneb System may help reduce the incidence of post-operative pulmonary complications in high-risk patients.

A 419-patient study found that patients using the Metaneb System combined with standard respiratory therapy spent 1.6 fewer days in the hospital on average compared to the group receiving standard respiratory therapy alone.

Hill-Rom’s Metaneb System combines secretion clearance, lung expansion therapy and aerosol drug-delivery to help keep a patient’s lungs clean following a surgical procedure.

“The occurrence of postoperative pulmonary complications in high-risk surgical patients is associated with increased morbidity and worse outcomes,” Dr. Toan Huynh of the Carolinas HealthCare System said in prepared remarks. “As much as 40% of patients may have trouble breathing once a procedure is completed, which is why today’s news is such an advance. It’s important to identify patients who may be at risk for PPCs, be vigilant while they undergo surgery, and use aggressive pulmonary treatments to reduce the risk of complications and get them back home. We believe these results contribute to best clinical practice in this area.”

“These data represent a potential breakthrough for clinicians and their patients. We already know that PPCs lead to significant health issues and increased length of hospital stay if they are not treated immediately and aggressively,” Dr. Carlos Urrea, VP of medical affairs for Hill-Rom, added.

“We are very pleased to see these results, which support the use of the Metaneb System as part of an overall prevention strategy to reduce complications and lower associated costs per patient.”

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Drug-Device Combinations, Featured, Pharmaceuticals, Respiratory, Surgical, Wall Street Beat Tagged With: Hill-Rom Holdings

IN CASE YOU MISSED IT

  • Nuvo, Sheba Medical Center develop AI-powered gestational diabetes management platform
  • Verily’s Onduo, Sword Health collaborate on virtual diabetes care
  • Shareholder lawsuit over BD’s Alaris pumps recall moves forward
  • Embecta stock soars on first full-quarter results after BD spinoff
  • Abbott will spend $450M to up FreeStyle Libre production in Ireland

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS